Intellia Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $23,017 | $13,782 | $14,245 | $16,627 |
Gross Profit | 17,002 | -65,167 | 14,245 | 16,627 |
EBITDA | -95,409 | -96,388 | -107,522 | -118,309 |
EBIT | -95,786 | -101,324 | -109,996 | -120,807 |
Net Income | -95,786 | -101,324 | -101,255 | -114,329 |
Net Change In Cash | 23,017 | 13,782 | 14,245 | 16,627 |
Free Cash Flow | -69,411 | -76,928 | -99,861 | -149,665 |
Cash | 155,464 | 193,389 | 156,172 | 126,880 |
Basic Shares | 108,376 | 110,188 | 103,732 | 103,500 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $67,671 | $57,877 | $36,275 | $52,121 |
Gross Profit | 51,748 | 47,592 | 27,299 | 44,549 |
EBITDA | -396,771 | -523,978 | -506,315 | -450,592 |
EBIT | -412,694 | -534,263 | -515,291 | -458,164 |
Net Income | -412,694 | -519,021 | -481,192 | -474,186 |
Net Change In Cash | 67,671 | 57,877 | 36,275 | 52,121 |
Cost of Revenue | 409,977 | |||
Free Cash Flow | -354,658 | -354,658 | -408,071 | -391,677 |
Cash | 155,464 | 189,182 | 226,748 | 523,506 |
Basic Shares | 108,376 | 98,849 | 88,770 | 76,972 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.83 |
2025-09-30 | -$0.92 |
2025-06-30 | -$0.98 |
